Oncopeptides AB
http://www.oncopeptides.se/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncopeptides AB
AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab
European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, should be fast-tracked through the EU evaluation system once the companies file for approval.
New EU Filings
Y-mAbs Therapeutics' omburtamab and Oncopeptides' melflufen are among 13 potential new treatments that have been submitted for pan-EU approval.
Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule